Characterization, Anti-lung Cancer Activity, and Cytotoxicity of Bio-synthesized Copper Nanoparticles by Thymus fedtschenkoi Leaf Extract

A Dehnoee, R Javad Kalbasi, MM Zangeneh… - Journal of Cluster …, 2024 - Springer
Today propose diverse techniques to remedy cancer and nanotechnology is one of the most
effective cancer treatments. In this study, we detail a simple and environmentally friendly …

The hypervariable region of K-Ras4B governs molecular recognition and function

H Abdelkarim, A Banerjee, P Grudzien… - International journal of …, 2019 - mdpi.com
The flexible C-terminal hypervariable region distinguishes K-Ras4B, an important proto-
oncogenic GTPase, from other Ras GTPases. This unique lysine-rich portion of the protein …

Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces …

MD Gregory, K Ofosu-Asante, JMS Lazarte, PE Puente… - PloS one, 2024 - journals.plos.org
KRAS mutations are the most common oncogenic mutations in lung adenocarcinoma in
Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of …

Haimufang decoction, a Chinese medicine formula for lung cancer, arrests cell cycle, stimulates apoptosis in NCI-H1975 cells, and induces M1 polarization in RAW …

WP Ma, SM Hu, YL Xu, HH Li, XQ Ma, BH Wei… - … medicine and therapies, 2020 - Springer
Background Lung cancer has the highest morbidity and mortality in the world and novel
treatment strategies are still needed. Haimufang decoction (HMF) is a patented clinical …

Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion

JMS Lazarte, NS Lamango - Biomedicines, 2024 - mdpi.com
Prognoses for TNBC remain poor due to its aggressive nature and the lack of therapies that
target its “drivers”. RASA1, a RAS-GAP or GTPase-activating protein whose activity inhibits …

[HTML][HTML] Two GEO MicroRNA expression profile based high-throughput screen to identify microRNA-31-3p regulating growth of medullary thyroid carcinoma cell by …

M Jiang, X Shi, H Zhu, W Wei, J Li - Medical science monitor …, 2019 - ncbi.nlm.nih.gov
Background Medullary thyroid carcinoma (MTC), a rare type of thyroid cancer, is a big
challenge in clinical treatment. However, the pathogenesis of MTC remains poorly …

Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors

N Tawfeeq, Y Jin, NS Lamango - Cancers, 2021 - mdpi.com
Simple Summary RAS G-protein genes are frequently mutated and drive the progression of
about 30% of human cancers. Polyisoprenylated cysteinyl amide inhibitors (PCAIs) offer a …

Polyisoprenylated cysteinyl amide inhibitors: a novel approach to controlling cancers with hyperactive growth signaling

NS Lamango, AT Nkembo, E Ntantie… - Current medicinal …, 2021 - benthamdirect.com
Aberrant activation of monomeric G-protein signaling pathways drives some of the most
aggressive cancers. Suppressing these hyperactivities has been the focus of efforts to obtain …

[PDF][PDF] Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors. Cancers (Basel). 2021; 13: 5757

N Tawfeeq, Y Jin, NS Lamango - 2021 - pdfs.semanticscholar.org
Abnormalities of the MAPK pathway play vital roles in cancer initiation and progression. RAS
GTPases that are key upstream mediators of the pathway are mutated in 30% of human …

Targeting KRAS Mutant Cancers with Polyisoprenylated Cysteinyl Amide Inhibitors

N Tawfeeq - 2021 - search.proquest.com
Abnormalities of the MAPK pathway play vital roles in cancer initiation and progression. RAS
GTPases that are key upstream mediators of the pathway are mutated in 20%–30% of …